Relay Therapeutics’s $400 Million Round Funding

Cooley advised SoftBank Vision Fund on leading Relay Therapeutics’ $400 million Series C financing.

According to Relay, proceeds from this financing are anticipated to be used to accelerate the implementation of its long-term strategy. It will support the expansion of the company’s discovery efforts, advance existing programs into the clinic and bolster its broad platform and diverse team.

Relay is committed to creating medicines that will have a transformative impact on patients by building a unique discovery platform centered on understanding how the conformation of proteins relate to function.

Cooley advised SoftBank Vision Fund with a team including Matthew Bartus (Picture), Bradley Libuit, Zander Olsson, Catherine O. Liang, Philip Merksamer, Christopher Kimball, Lila Hope, Blake Martell, Emily Iannarelli, Ross Eberly, Chen Chen, Pengli Li, Erin Estevez, TJ Graham, Sharon Connaughton, Patrick M. Stewart, Kimberly Nguyen, Adit Khorana, Alan Ai, Madhuri Roy, Kevin King, Howard Morse, Mika Reiner Mayer and Aaron Pomeroy.

Involved fees earner: Alan Ai – Cooley LLP; Matthew Bartus – Cooley LLP; Chen Chen – Cooley LLP; Sharon Connaughton – Cooley LLP; Ross Eberly – Cooley LLP; Erin Estevez – Cooley LLP; TJ Graham – Cooley LLP; Lila Hope – Cooley LLP; Emily Iannarelli – Cooley LLP; Adit Khorana – Cooley LLP; Christopher Kimball – Cooley LLP; Kevin King – Cooley LLP; Pengli Li – Cooley LLP; Catherine Liang – Cooley LLP; Bradley Libuit – Cooley LLP; Blake Martell – Cooley LLP; Philip Merksamer – Cooley LLP; Howard Morse – Cooley LLP; Kimberly Nguyen – Cooley LLP; Zander Olsson – Cooley LLP; Aaron Pomeroy – Cooley LLP; Mika Reiner Mayer – Cooley LLP; Madhuri Roy – Cooley LLP; Patrick Stewart – Cooley LLP;

Law Firms: Cooley LLP;

Clients: SoftBank Vision Fund;


Author: Ambrogio Visconti